Shape’s mantra seems a far cry from the health and fitness publications of old. It also significantly strays a bit from the current Men’s Health magazine, which still happily screams at you to get off your ass, already. The Jan/Feb top headline: “Get Back In Shape!”, which sounds like an angry command more than a helpful title to a magazine article. The tagline to Men’s Health is “tons of useful stuff,” which all seem to incorporate words like “hot,” “beast,” and “crush.” Inside, the “useful stuff” ranges from the difference between beef stock and beef broth to how to dump someone before Valentine’s Day. And reps. Lots of reps. These guys love reps.
Even just that single-page layout in Women’s Health is a huge step in the right direction. Seeing more normal-size women on the pages of fashion magazines and catalogues may actually be more inspirational than urging readers to take “more ‘me time.’” It’s also another area where women’s health magazines are surpassing the men’s version: The only non-cut men in Men’s Health are seen in “before” pictures in fitness makeovers. This is despite the fact that 90 percent of men are “overfat,” as the magazine itself reported. Non-six-pack men aren’t missing from the magazine because they’re difficult to find, same as non-size- 2s on the women’s side.
Calcium: For adult women aged 19-50, the USDA recommended daily allowance is 1,000 mg/day. For women over 50, the recommended daily allowance is 1,200 mg/day. Good sources of calcium include dairy products, leafy green vegetables, certain fish, grains, tofu, cabbage, and summer squash. Your body cannot take in more than 500 mg at any one time and there’s no benefit to exceeding the recommended daily amount.
Changes in the way research ethics was visualised in the wake of the Nuremberg Trials (1946), led to an atmosphere of protectionism of groups deemed to be vulnerable that was often legislated or regulated. This resulted in the relative underrepresentation of women in clinical trials. The position of women in research was further compromised in 1977, when in response to the tragedies resulting from thalidomide and diethylstilbestrol (DES), the United States Food and Drug Administration (FDA) prohibited women of child-bearing years from participation in early stage clinical trials. In practice this ban was often applied very widely to exclude all women. Women, at least those in the child-bearing years, were also deemed unsuitable research subjects due to their fluctuating hormonal levels during the menstrual cycle. However, research has demonstrated significant biological differences between the sexes in rates of susceptibility, symptoms and response to treatment in many major areas of health, including heart disease and some cancers. These exclusions pose a threat to the application of evidence-based medicine to women, and compromise to care offered to both women and men.